BIOMAT Database Logo BIOMAT Database Logo

Comparative in-vitro activity of fleroxacin against 480 nosocomial isolates. 1994

D Sofianou, and F Frantzidou, and A Tsakris
Department of Medical Microbiology, Aristotelian University of Thessaloniki, Greece.

A total of 480 recent clinical isolates were tested for their susceptibility to fleroxacin, norfloxacin, ofloxacin, gentamicin, piperacillin, cefoxitin, cefotaxime and imipenem. Fleroxacin showed potent activity against strains of Enterobacteriaceae, Acinetobacter spp. and gentamicin-sensitive Pseudomonas aeruginosa with MIC90s ranging from 0.06 to 2 mg/l, although the MIC90 for gentamicin-resistant P. aeruginosa strains was as high as 32 mg/l. The drug exhibited excellent activity against staphylococci, both methicillin-sensitive and -resistant. The overall activity of fleroxacin was comparable with that of norfloxacin and ofloxacin and higher than that exhibited by gentamicin and beta-lactam antibiotics tested.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D003428 Cross Infection Any infection which a patient contracts in a health-care institution. Hospital Infections,Nosocomial Infections,Health Care Associated Infection,Health Care Associated Infections,Healthcare Associated Infections,Infection, Cross,Infections, Hospital,Infections, Nosocomial,Cross Infections,Healthcare Associated Infection,Hospital Infection,Infection, Healthcare Associated,Infection, Hospital,Infection, Nosocomial,Infections, Cross,Infections, Healthcare Associated,Nosocomial Infection
D006090 Gram-Negative Bacteria Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method. Gram Negative Bacteria
D006094 Gram-Positive Bacteria Bacteria which retain the crystal violet stain when treated by Gram's method. Gram Positive Bacteria
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D016576 Fleroxacin A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE. AM-833,Quinodis,Ro 23-6240,AM 833,AM833,Ro 23 6240,Ro 236240

Related Publications

D Sofianou, and F Frantzidou, and A Tsakris
Comparative in vitro activity of cefepime against nosocomial isolates.
October 1997, Journal of chemotherapy (Florence, Italy),
D Sofianou, and F Frantzidou, and A Tsakris
Comparative in vitro activity of cefetamet and fleroxacin against anaerobic bacteria.
December 1987, European journal of clinical microbiology,
D Sofianou, and F Frantzidou, and A Tsakris
[In vitro antibacterial activity of fleroxacin (FLRX) against clinical isolates from bacterial enteritis].
November 1994, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
D Sofianou, and F Frantzidou, and A Tsakris
Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.
October 1989, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
D Sofianou, and F Frantzidou, and A Tsakris
Comparative in-vitro activity of fleroxacin and other 6-fluoroquinolones against mycobacteria.
October 1988, The Journal of antimicrobial chemotherapy,
D Sofianou, and F Frantzidou, and A Tsakris
In vitro activity of a new quinolone, rufloxacin, against nosocomial isolates.
January 1991, Chemotherapy,
D Sofianou, and F Frantzidou, and A Tsakris
In vitro activity of fleroxacin against multiresistant gram-negative bacilli isolated from patients with nosocomial infections.
August 1998, Intensive care medicine,
D Sofianou, and F Frantzidou, and A Tsakris
In-vitro activity of fleroxacin against Chlamydia trachomatis.
October 1988, The Journal of antimicrobial chemotherapy,
D Sofianou, and F Frantzidou, and A Tsakris
Comparative in vitro and in vivo activity of fleroxacin and ofloxacin against various mycobacteria.
September 1991, Tubercle,
D Sofianou, and F Frantzidou, and A Tsakris
Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin.
October 1988, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!